Antonia Rodríguez Izquierdo

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 726 citations · Full text

Medicine, Hematology, Oncology +12

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo‐Doménech et al. · Blood · 2020 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Herbert Eradat, Abraham Avigdor et al. · Blood · 2023 · 23 citations

Medicine, Geriatric Medicine, Oncology +8

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nancy L. Bartlett, Robert W. Chen, Eva Domingo‐Doménech et al. · Blood · 2018 · 16 citations

Medicine, Immunology, Oncology +17

Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Thomas E. Witzig, Lubomir Sokol, Won Seog Kim et al. · Blood Advances · 2024 · 12 citations · Full text

Medicine, Oncology, Pharmacology +17